<DOC>
	<DOCNO>NCT01216943</DOCNO>
	<brief_summary>This study investigate safety efficacy Triple Combination Therapy ( bimatoprost/brimonidine tartrate/timolol fix combination ophthalmic solution ) patient glaucoma ocular hypertension elevate intraocular pressure ( IOP ) brimonidine/timolol ophthalmic solution .</brief_summary>
	<brief_title>Safety Efficacy Triple Combination Therapy Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Glaucoma and/or ocular hypertension eye Requires IOPlowering treatment eye Other active ocular disease glaucoma ocular hypertension ( eg , uveitis , ocular infection severe dry eye ) Current anticipate use ocular medication study medication , except intermittent use artificial tear Use oral , injectable topical corticosteroid within 21 day Iridectomy laser peripheral iridotomy study eye within 3 month Uncomplicated cataract surgery study eye within 6 month Incisional glaucoma surgery study eye within 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>